CBP-501

Calmodulin Binding Peptide / Cell Penetrating Antitumor PeptideRx: InvestigationalCompound: Investigational

Also known as: CanBas-501, CBP501

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

CBP-501 is an investigational antitumor peptide that targets calmodulin signaling and the G2/M DNA damage checkpoint. It has been studied primarily in combination with cisplatin and pemetrexed for the treatment of malignant pleural mesothelioma and other solid tumors. Clinical trials have explored its ability to sensitize tumor cells to platinum-based chemotherapy.

Mechanism of Action

CBP-501 is a synthetic peptide derived from the calmodulin-binding domain of the cell division cycle 25 C (CDC25C) phosphatase. It binds calmodulin, inhibits the G2/M checkpoint, and sensitizes cancer cells to DNA-damaging agents. It also disrupts calmodulin-dependent signaling, impairs DNA damage repair, and promotes immunogenic cell death by enhancing tumor immunogenicity in combination with cisplatin.

Routes of Administration

Intravenous

Goals & Uses

  • Sensitization to cisplatin chemotherapyOncology / ChemosensitizationModerate
  • Immunogenic cell death inductionOncology / Immuno OncologyLow
  • Treatment of malignant pleural mesotheliomaOncology / Solid TumorModerate
  • G2/M checkpoint abrogation in cancer cellsOncology / Cell Cycle ModulationModerate

Contraindications

  • Severe renal impairmentOrganHighKidney function concerns
  • PregnancyPopulationHighPotential fetal risk or insufficient safety data
  • Severe hypersensitivity to CBP-501 or excipientsAllergy / HypersensitivityHigh

Adverse Effects

  • Neurotoxicity / peripheral neuropathyNeurologicalUncommon
  • Nausea and vomitingGastrointestinalCommon
  • FatigueGeneralCommonLow energy or tiredness
  • MyelosuppressionHematologicCommon
  • Infusion-related reactionsHypersensitivityUncommon
  • NephrotoxicityRenalUncommon

Drug Interactions

  • PemetrexedModerate
  • CisplatinModerate
  • Nephrotoxic agentsHigh

Population Constraints

  • Patients with pre-existing renal impairmentOrgan FunctionRelative
  • Pediatric patientsAgeRelative
  • Pregnant or breastfeeding womenReproductiveAbsolute

Regulatory Status

  • European UnionUnapprovedNo EMA approval; no known active EU trials as of available data.
  • United StatesInvestigationalEvaluated in Phase I/II clinical trials under IND; no FDA approval granted.
  • United KingdomUnknownNo MHRA approval known; status not clearly documented in public sources.

CBP-501 has not received FDA, EMA, or any other regulatory approval. It has been evaluated in Phase I and Phase II clinical trials in the United States and Japan, primarily in combination with cisplatin.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack